Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Nevada Lifileucel Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedAmbetter NevadaPolicy CP.PHAR.598

    Clinical Policy: Lifileucel (Amtagvi)

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.PHAR.598 alerts

    Get alerted when Policy CP.PHAR.598 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity coverage for lifileucel (Amtagvi), primarily for adults with unresectable or metastatic melanoma; applies to Commercial, HIM/ICHRA, and Medicaid lines of business.

    Policy Summary
    PayerAmbetter Nevada
    PolicyClinical Policy: Lifileucel (Amtagvi)
    Policy CodePolicy CP.PHAR.598
    Change TypeModified
    Effective DateFeb 1, 2024
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation supporting that the member meets all approval criteria for PDAC utilization management review.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added FDA-label-based requirements for concomitant IL-2 therapy, a resectable lesion, exclusion of uveal or ocular melanoma, and restrictions for prior organ allograft, TIL therapy, or CAR-T therapy.

    Prior authorization requests were redirected to Precision Drug Action Committee utilization management review.

    FDA-labeling updates added requirements for concomitant interleukin-2 therapy, documentation of at least one resectable lesion, confirmation that melanoma is not of known uveal or ocular origin, and restrictions related to prior organ allograft, TIL therapy, or CAR-T therapy.

    The ICHRA line of business was added during the 2026 annual review.

    Prior authorization reviews were redirected to the Precision Drug Action Committee Utilization Management Review process.

    The 2026 annual review added the ICHRA line of business.

    1 doseAuthorized Amtagvi administrations

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    7.5–72 × 10^9Viable T-cell dose range
    ≥ 1.5 cmMinimum resectable lesion size
    Up to 6IL-2 doses with course
    18+Minimum covered age

    Coverage Criteria

    Initial Therapy — Melanoma

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of unresectable or metastatic melanoma.
    • Prescribed by or in consultation with an oncologist.
    • Member is age 18 years or older.>= 18 years
      • Anti-PD-1 or PD-L1 therapy.
      • If BRAF V600 mutation positive, BRAF inhibitor therapy with or without a MEK inhibitor.
    • Amtagvi is prescribed in combination with interleukin-2 (IL-2) therapy, such as aldesleukin.

      Prior authorization may be required for IL-2 therapy.

    • Documentation that the member has at least one resectable lesion, or an aggregate of lesions resected, measuring at least 1.5 cm in diameter.>= 1.5 cm
    • Documentation that the member's melanoma is not of known uveal or ocular origin.
    • Member has not received an organ allograft, prior tumor-infiltrating lymphocyte (TIL) therapy, or prior chimeric antigen receptor T-cell (CAR-T) therapy, including Breyanzi, Kymriah, Tecartus, Yescarta, or Carvykti.
      • Dose contains a minimum of 7.5 × 10⁹ viable T cells.>= 7.5 × 10⁹ viable T cells
      • Dose does not exceed a single administration of 72 × 10⁹ viable T cells.<= 72 × 10⁹ viable T cells

    Initial Therapy — Other Diagnoses/Indications

    Covered when ONE of the following pathways applies:

    ONE of the following

    • Recently changed FDA-approved labeling

      • The drug has undergone a label change within the last 6 months, such as a newly approved indication, age expansion, or new dosing regimen, that is not yet reflected in this policy.
      • Refer to the applicable policy

        • For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), refer to the no coverage criteria policy for the applicable line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, or CP.PMN.255 for Medicaid.
        • For drugs not on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), refer to the non-formulary policy for the applicable line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, or CP.PMN.16 for Medicaid.

    Continuation Therapy

    Continuation therapy is evaluated under the applicable pathway:

    Applicable continuation pathway

    • Melanoma

      • Continued therapy will not be authorized because Amtagvi is indicated to be dosed one time only.
    • Other diagnoses/indications

      • ONE of the following

        • Recently changed FDA-approved labeling

          • The drug has undergone a label change within the last 6 months, such as a newly approved indication, age expansion, or new dosing regimen, that is not yet reflected in this policy.
          • Refer to the applicable policy

    For melanoma coverage, the member's disease must not be of known uveal or ocular origin. Amtagvi requires IL-2 administration after infusion to stimulate the TIL cells. A resectable lesion, or aggregate of lesions resected, measuring at least 1.5 cm is required to provide adequate tumor volume for T-cell amplification. Safety and efficacy are unknown in patients with uveal/ocular melanoma or previous organ allograft or prior cell-transfer therapy.

    Amtagvi is limited to a single administration containing no more than 72 × 10⁹ viable T cells. Initial approval is for 3 months for one dose, with up to 6 doses of IL-2 therapy (aldesleukin).

    Coverage is excluded when the member has received a prior organ allograft, prior TIL therapy, or prior CAR-T therapy, including Breyanzi, Kymriah, Tecartus, Yescarta, or Carvykti.

    Non-FDA-approved indications not addressed in this policy are not covered unless sufficient documentation of efficacy and safety is provided in accordance with the applicable off-label use policy: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid, or applicable evidence of coverage documents.

    Coding and Dose Parameters

    HCPCS CodesHCPCS
    C9399Unclassified drugs or biologicals
    J9999Not otherwise classified, antineoplastic drugs
    HCPCS CodesHCPCS
    C9399Unclassified drugs or biologicals
    J9999Not otherwise classified, antineoplastic drugs
    Viable T-cell dose
    Minimum viable T-cell dose7.5 x 10^9 viable T cells
    Maximum viable T-cell dose72 x 10^9 viable T cells
    Resectable lesion size
    Minimum lesion or aggregate diameterAt least 1.5 cm in diameter

    Prior Authorization and Provider Requirements

    Prior Authorization

    PDAC Review and Submission Required

    All requests require Precision Drug Action Committee (PDAC) Utilization Management Review. Submit the prior authorization request through the PDAC process and include documentation supporting that the member meets all applicable approval criteria; refer to CC.PHAR.21 for process details.

    Billing Rule

    Single-Course Authorization

    Initial approval is limited to a 3-month authorization for one Amtagvi administration, with up to six doses of interleukin-2 therapy (such as aldesleukin). Prior authorization may also be required for the IL-2 therapy.

    • One Amtagvi dose only
    • Up to 6 IL-2 doses

    Clinical Background

    Lifileucel (Amtagvi) is an autologous tumor-infiltrating lymphocyte (TIL) cell therapy. TIL cells are obtained from a resected tumor, expanded, and administered as a single infusion; IL-2, such as aldesleukin, is administered after infusion to stimulate the TIL cells. The FDA-indicated population is adults with unresectable or metastatic melanoma previously treated with an anti-PD-1 or PD-L1 therapy and, when BRAF V600 mutation-positive, a BRAF inhibitor with or without a MEK inhibitor.

    Definitions and Abbreviations

    BRAF
    BRAFB-Raf proto-oncogene, serine/threonine kinase
    CAR
    CARChimeric antigen receptor
    IL-2
    IL-2Interleukin-2
    PD-1
    PD-1Programmed death receptor-1

    Initial Therapy Criteria

    Initial Melanoma Authorization

    Melanoma must meet ALL initial approval criteria:

    Initial melanoma authorization

    • Diagnosis, age, and prescriber: The member has unresectable or metastatic melanoma, is age 18 years or older, and is prescribed Amtagvi by or in consultation with an oncologist.Age ≥ 18 years
    • Required prior therapy: The member has documented disease progression, inadequate response, or intolerance to anti-PD-1 or PD-L1 therapy. If BRAF V600 mutation-positive, the member also has documented disease progression, inadequate response, or intolerance to BRAF inhibitor therapy with or without a MEK inhibitor.
    • Interleukin-2 combination: Amtagvi is prescribed in combination with interleukin-2 therapy, such as aldesleukin.

    Continuation Criteria

    One-Time Treatment

    Melanoma continuation therapy:

    One-time treatment: Continued Amtagvi therapy will not be authorized because Amtagvi is indicated to be dosed one time only.One dose only

    Approval duration is not applicable.

    Required Prior Therapy

    StepRequired prior therapyCoverage requirement
    1Anti-PD-1 or PD-L1 therapyDocumented disease progression, inadequate response, or intolerance while receiving therapy. Examples include nivolumab with ipilimumab, nivolumab with relatlimab, nivolumab, or pembrolizumab.
    StepRequired prior therapyCoverage requirement
    2For BRAF V600 mutation-positive melanoma: BRAF inhibitor therapy with or without a MEK inhibitorDocumented disease progression, inadequate response, or intolerance. This requirement applies in addition to prior anti-PD-1 or PD-L1 therapy.

    Quantity Limits

    Amtagvi (lifileucel)
    AdministrationSingle administration
    Viable T-cell dose range7.5 x 10^9 to 72 x 10^9 viable T cells
    IL-2 therapy (e.g., aldesleukin)
    Maximum course quantityUp to 6 doses
    Policy Summary
    PayerAmbetter Nevada
    PolicyClinical Policy: Lifileucel (Amtagvi)
    Policy CodePolicy CP.PHAR.598
    Change TypeModified
    Effective DateFeb 1, 2024
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation supporting that the member meets all approval criteria for PDAC utilization management review.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Dose ParametersPrior Authorization and Provider RequirementsClinical BackgroundDefinitions and AbbreviationsInitial Therapy CriteriaContinuation CriteriaRequired Prior TherapyQuantity Limits

    Other requested use

    • The requested use, including diagnosis, age, or dosing regimen, is not specifically listed under Section III, Diagnoses/Indications for which coverage is NOT authorized.
    • The recently changed FDA-approved labeling pathway above does not apply.
    • Refer to the off-label use policy for the applicable line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid.
    For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), refer to the no coverage criteria policy for the applicable line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, or CP.PMN.255 for Medicaid.
  1. For drugs not on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), refer to the non-formulary policy for the applicable line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, or CP.PMN.16 for Medicaid.
  2. Other requested use

    • The requested use, including diagnosis, age, or dosing regimen, is not specifically listed under Section III, Diagnoses/Indications for which coverage is NOT authorized.
    • The recently changed FDA-approved labeling pathway above does not apply.
    • Refer to the off-label use policy for the applicable line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid.
  3. Prior Authorization

    Route Reviews Through PDAC

    Route prior authorization reviews for Lifileucel (Amtagvi) through the PDAC Utilization Management Review process rather than a standard standalone review.

    • See CC.PHAR.21 for PDAC process details
    Step Therapy

    Required Prior BRAF-Targeted Therapy

    Document disease progression, inadequate response, or intolerance while on prior targeted therapy when the melanoma is BRAF V600 mutation-positive. The required therapy is a BRAF inhibitor, with or without a MEK inhibitor.

    • Examples include BRAF/MEK combination targeted therapy
    • Applicable to BRAF V600 mutation-positive melanoma
    Step Therapy

    Required Prior Checkpoint Therapy

    Document disease progression, inadequate response, or intolerance while on prior anti-PD-1 or PD-L1 therapy before requesting Amtagvi.

    • Examples include nivolumab-, pembrolizumab-, or other anti-PD-1/PD-L1-containing regimens

    Unsupported block type: documentation the provider must supply

    Unsupported block type: documentation

    Unsupported block type: prior_auth

    Denial Risk

    Failure to Meet Coverage Criteria

    Coverage may be denied when required criteria are not met, including the diagnosis, oncology prescribing requirement, age requirement, prior therapies, lesion size or resectability, melanoma origin, dose limits, or other policy conditions.

    • Member must be at least 18 years old
    • Diagnosis must be unresectable or metastatic melanoma
    • Dose must contain at least 7.5 × 109 viable T cells and not exceed a single administration of 72 × 109 viable T cells
    Denial Risk

    Repeat Treatment Not Authorized

    Continuation requests for melanoma are not authorized because Amtagvi is indicated to be administered one time only. Continued-therapy approval duration is not applicable.

    • One-time treatment
    • No repeat or continuation authorization
    Denial Risk

    Disqualifying Prior Therapy or Transplant

    Coverage may be denied if the member has received a prior organ allograft, TIL therapy, or CAR-T therapy before the request.

    • Prior organ allograft is disqualifying
    • Prior tumor-infiltrating lymphocyte (TIL) therapy is disqualifying
    • Prior chimeric antigen receptor T-cell (CAR-T) therapy is disqualifying
    PD-L1
    PD-L1Programmed death-ligand 1
    TIL
    TILTumor infiltrating lymphocytes
  4. Resectable lesion: Documentation establishes at least one resectable lesion, or an aggregate of lesions resected, measuring at least 1.5 cm in diameter.≥ 1.5 cm
  5. Melanoma origin and treatment history: Documentation establishes that the melanoma is not of known uveal or ocular origin and that the member has not received an organ allograft, prior tumor-infiltrating lymphocyte therapy, or prior chimeric antigen receptor T-cell therapy.
  6. Requested dose: The requested dose contains at least 7.5 x 10^9 viable T cells and does not exceed a single administration of 72 x 10^9 viable T cells.7.5 x 10^9 to 72 x 10^9 viable T cells
  7. FDA-Labeling Criteria

    The following FDA-labeling requirements apply to initial Amtagvi therapy:

    FDA-labeling requirements

    • Amtagvi is prescribed in combination with interleukin-2 therapy.
    • Documentation establishes at least one resectable lesion.
    • Documentation establishes that the member's melanoma is not of known uveal or ocular origin.
    • The member has not received a prior organ allograft, prior tumor-infiltrating lymphocyte therapy, or prior chimeric antigen receptor T-cell therapy.